| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 2.37 µM (EGFR)[3]
Delphinidin 3-glucoside chloride targets multiple cellular pathways. It is an inhibitor of the epidermal growth factor receptor (EGFR). It also acts as a potent antioxidant and protects against mitochondrial dysfunction. Its mechanism of action involves scavenging reactive oxygen species and modulating signaling pathways. It is a dietary anthocyanin with potential health benefits. |
|---|---|
| ln Vitro |
In vitro, Delphinidin 3-glucoside chloride demonstrates potent antioxidant activity. It inhibits EGFR and protects against oxidized low-density lipoprotein-induced mitochondrial dysfunction in vascular endothelial cells. Its activity is typically assessed in antioxidant assays (e.g., DPPH, ABTS) and in cell-based assays measuring cell viability, ROS levels, and mitochondrial function.
|
| ln Vivo |
In vivo studies for Delphinidin 3-glucoside chloride are not extensively detailed in the provided literature. As a dietary anthocyanin, it has potential for in vivo applications in cardiovascular protection and cancer prevention. Studies in animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. Its antioxidant properties suggest it could have beneficial effects in vivo.
|
| Enzyme Assay |
For non-cellular enzyme/receptor binding studies, Delphinidin 3-glucoside chloride's activity can be evaluated in EGFR inhibition assays. Purified EGFR is incubated with ATP, a substrate, and varying concentrations of the compound. Kinase activity is measured, and IC50 values are calculated. Its antioxidant activity can be assessed using standard in vitro assays such as DPPH or ABTS radical scavenging.
|
| Cell Assay |
For in vitro cellular experiments, vascular endothelial cells or other cell lines are cultured and treated with Delphinidin 3-glucoside chloride at various concentrations. Cell viability is assessed using MTT or similar assays. Mitochondrial function is assessed by measuring membrane potential or ATP levels. ROS levels are measured using fluorescent probes. The compound's ability to inhibit EGFR is confirmed by measuring downstream signaling.
|
| Animal Protocol |
In vivo animal studies for Delphinidin 3-glucoside chloride are not extensively documented. However, its potential for in vivo applications in cardiovascular protection is suggested by its in vitro activity. Studies in animal models of atherosclerosis or other cardiovascular diseases would be needed to evaluate its in vivo efficacy. The compound could be administered orally.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Delphinidin 3-glucoside chloride are not extensively detailed in the provided sources. It has a molecular weight of 500.84 and a purity of 95%. As an anthocyanin glycoside, it is expected to have limited oral bioavailability due to poor absorption and extensive metabolism. Comprehensive pharmacokinetic studies are needed to fully characterize its ADME properties.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Delphinidin 3-glucoside chloride is not explicitly detailed in the provided sources. As a naturally occurring dietary compound, it is likely to have a favorable safety profile. However, standard laboratory safety precautions should be followed when handling it. It is intended for research use only and is not for human therapeutic applications.
|
| References |
|
| Additional Infomation |
Delphinidin-3-glucoside is an anthocyanin glycoside.
See also: Myrciaria dubia fruit (partial). Delphinidin 3-glucoside chloride is a natural anthocyanin with a molecular formula of C21H21ClO12 and a molecular weight of 500.84. It is a potent antioxidant and an EGFR inhibitor. It protects against mitochondrial dysfunction in vascular endothelial cells. This research compound is for laboratory use only and has not been approved for clinical applications. |
| Molecular Formula |
C21H21CLO12
|
|---|---|
| Molecular Weight |
500.84
|
| Exact Mass |
500.072
|
| CAS # |
6906-38-3
|
| PubChem CID |
165558
|
| Appearance |
Purple to black solid powder
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
641
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O.[Cl-]
|
| InChi Key |
ZJWIIMLSNZOCBP-BTTVDUMLSA-N
|
| InChi Code |
InChI=1S/C21H20O12.ClH/c22-6-15-17(28)18(29)19(30)21(33-15)32-14-5-9-10(24)3-8(23)4-13(9)31-20(14)7-1-11(25)16(27)12(26)2-7;/h1-5,15,17-19,21-22,28-30H,6H2,(H4-,23,24,25,26,27);1H/t15-,17-,18+,19-,21-;/m1./s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 10 mg/mL (19.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9966 mL | 9.9832 mL | 19.9665 mL | |
| 5 mM | 0.3993 mL | 1.9966 mL | 3.9933 mL | |
| 10 mM | 0.1997 mL | 0.9983 mL | 1.9966 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
